Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib: A Population-Based Retrospective Cohort Study
Authors' conclusion
Osimertinib use was associated with an increased risk for HF hospitalization.
Study context
- Population
- Patients diagnosed with lung cancer who received cancer therapy, April 2008–December 2021median follow-up 173 days
- Participants
- 11,391 vs 108,144
- Exposure
- Osimertinib vs control therapy
- Osimertinibn = 11,391
- Controln = 108,144reference
- Outcome
- Heart failure (HF) hospitalization
- Follow-up
- During the treatment period
Methodological detailspropensity score matching, Japanese claims database
- Propensity score matching
- Japanese claims database
Main finding
As reported in the abstract
HF hospitalization
Osimertinib vs ControlSubdistribution hazard ratio (95% CI)P value
Multivariable analysis
2.56(2.07–3.18)
P < 0.001After propensity score matching
2.29(1.62–3.24)
P < 0.001Observational data: associations, not effects.
Original publication
Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib: A Population-Based Retrospective Cohort Study. JACC CardioOncol. Published 11 September 2025. doi:10.
Summarised from the published abstract; every number is checked against it